COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Patients with cancer are at an increased risk of serious complications and death from COVID-19, which is heightened by being aged 40 years or older, major medical comorbidities, poor performance status, the presence of haematological malignancies, and the receipt of immunosuppressive cancer therapies. Early pivotal randomised trials of COVID-19 vaccines showed their high level of safety and efficacy, but excluded individuals on immunosuppressive therapies, which includes most patients with cancer, leaving uncertainty about vaccine efficacy and safety in this setting. Reduced humoral or cellular immune vaccine responses have been observed in patients receiving cancer chemotherapy or other immunosuppressive treatments, most notably in patients with multiple myeloma or other B-cell malignancies and in those receiving B-cell-depleting or cellular therapies (...)
The Lancet Oncology , commentaire en libre accès, 2021